

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0150003	Application No. 10/010,283
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Carl-Axel Bauer et al.	
		Filing Date November 13, 2001	Group Art Unit 1617

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	1	Notice of Opposition, filed by Ranbaxy Laboratories Limited, opposing the grant of Patent Application No.190791 by Intellectual Property India (India Patent Office), dated June 1, 2006 (21 pages).
	2	Reply statement before the Opposition Board, Patent Office, Delhi; submitted on behalf of AstraZeneca, dated July 27, 2006 (6 pages).
	3	Affidavit of Jan William Trofast, before the Opposition Board, Patent Office, Delhi; submitted on behalf of AstraZeneca, dated September 13, 2006 (7 pages).
	4	Opponent Response in Opposition to Patent No. 19071, submitted by Lakshmi Kumaran & Sridharan, dated November 3, 2006 (6 pages).

Examiner Signature /Jennifer Kim/	Date Considered 02/01/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JK/